NetworkNewsBreaks Archive - Page 2146 of 2170

TuesdayNov 29, 2016 2:00 pm

NetworkNewsBreaks – Dataram Corp. (DRAM) Shares Surge on Finalized Agreement to Acquire U.S. Gold Corp.

Dataram (NASDAQ: DRAM), an independent manufacturer of memory products and provider of performance solutions, is trading 34% higher mid-day after announcing it has finalized its definitive agreement to acquire U.S. Gold Corp., a gold exploration and development company that controls multiple mining leases and mineral rights throughout the U.S., and its subsidiaries. The companies are working to finalize the preliminary S-4/Proxy, which they intend to file with NASDAQ next month. Once the NASDAQ review is completed, Dataram will file a definitive S-4/Proxy and will formally present the merger and associated consideration to the shareholders in early 2017 for review and…

TuesdayNov 29, 2016 1:05 pm

NetworkNewsBreaks – Cogint, Inc.’s (COGT) Core Technologies Set Pace for Continued Growth

Shares of Cogint (NASDAQ: COGT) are up nearly 9% in morning trade, likely lifted by gains in the broader technology sector. The data analytics company is focused on harnessing powerful analytics to quickly and efficiently transform data into intelligence. Three key brands serve as the foundation for Cogint’s operations: Fluent, which combines data science and real-time consumer interaction to serve personalized ads that help brands acquire loyal customers; IDI, a leading-edge data and investigative solutions provider leveraging its CORE™-powered next-gen data fusion platform to deliver actionable intelligence to the risk management industry; and Q Interactive, a direct publisher focused on…

TuesdayNov 29, 2016 1:03 pm

NetworkNewsBreaks – Great Basin Scientific (GBSN) Shares Climb on New Patent for PCR Amplification Suppressor

Great Basin Scientific (OTCQB: GBSN) is trading higher after announcing that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 9,434,999 for the company’s amplification suppressor. This technology blocks detection of contaminants – such as staphylococcus - that may result in a false positive result and potential misdiagnosis of a patient when testing clinical specimens such as blood specimens, nasal swabs, or bronchial lavages from suspected pneumonia. The amplification suppressor is used in the company’s Staph ID/R Blood Culture Panel and is being utilized in the SA Nasal Screen Test, scheduled for clinical trial in the first half of…

TuesdayNov 29, 2016 1:02 pm

NetworkNewsBreaks – Net Element, Inc. (NETE) Positioned for its Share in Multi-Trillion Dollar Market

With an innovative portfolio of mobile payments and value-added transactional services, Net Element (NASDAQ: NETE) is squared off to capture its share of the $1.2 trillion global e-commerce market, as well as of the multi-billion dollar point-of-sale terminals market. “Those are awfully large pies for the taking, and global technology-driven company Net Element … is laying the table with a smorgasbord of products for retailers and consumers alike. Net Element’s transactional services business has been doing particularly well. A report from Zack’s Small-Cap Research (http://nnw.fm/iQK00) detailed that revenues from the company’s ‘US card processing services, grew a healthy 42.9% from…

TuesdayNov 29, 2016 1:00 pm

NetworkNewsBreaks – FDA Grants PharmaCyte Biotech (PMCB) Pre-IND Meeting for Pancreatic Cancer Therapy; Shares Soar

PharmaCyte Biotech (OTCQB: PMCB) shares are up 46% mid-morning on news the company has been granted a Pre-Investigational New Drug (Pre-IND) meeting with the FDA’s Center for Biologics Evaluation and Research (CBER) regarding the company’s planned clinical trial for patients with locally advanced, inoperable pancreatic cancer (LAPC). The pre-IND meeting is the next step in PharmaCyte’s plans to advance its pancreatic cancer therapy into a clinical trial and eventual FDA approval. To view the full press release, visit: http://nnw.fm/fAD6W About PharmaCyte Biotech PharmaCyte Biotech a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based…

TuesdayNov 29, 2016 10:57 am

NetworkNewsBreaks – eXp World Holdings’ (EXPI) Brokerage Division Warrants Analysis Update at Fundamental Research

After the release of its record financial results in the third quarter of 2016, eXp World Holdings (OTCQB: EXPI) was analyzed by Fundamental Research Corp. The independent research group updated its analysis with an increased fair value estimate and revenue forecast. “eXp Realty has remained the driving force behind the group’s increase throughout the last few months, as it is currently one of the fastest growing real estate brokerages on the U.S. market, having nearly tripled in size and operations since inception. The Agent-Owned Cloud Brokerage™ currently has more than 2,200 real estate professionals serving 41 states, the District of…

TuesdayNov 29, 2016 10:54 am

NetworkNewsBreaks – Agora Holdings, Inc.’s (AGHI) FRAME Increases Social Media Efficiencies

Agora Holdings (OTC: AGHI) recently introduced its FRAME social media management software for businesses. This new technology enables companies to dedicate less time to social media while still furthering their growth, resulting in a more cost-effective strategy. “In addition to a range of customer care tools, analytics, and reporting, the social media management software contributes hugely to an organization’s bottom line, saving it time and money. FRAME allows businesses to publish content that is not only relevant but also fits in perfectly with strategic objectives. FRAME is currently integrated with Twitter (NYSE: TWTR), Facebook (NASDAQ: FB), and Instagram, and it…

MondayNov 28, 2016 2:50 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on November 28, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PZRX 143.37% – News: PRX-OTC receives Orphan Drug Designation EMGL 47.06% – News: Posts Q3 financial results, GAAP revenues increase 133% EPIX 31.93% – News: Secures $10 million term loan REPH 23.58%– News: Positive results from second phase III clinical trial for Meloxicam MRIC 17.92% – News: ClearPoint® will be exhibited at AES Annual Meeting December 2 - 6, 2016, in Houston STEM 11.79% – News: Merges with Microbot Medical; will begin trading on…

MondayNov 28, 2016 1:13 pm

NetworkNewsBreaks – Neovasc, Inc. (NVCN) Receives Regulatory Approval for TIARA II CE Mark Study

Neovasc (NASDAQ: NVCN) (TSX: NVC) says it has received both regulatory and ethics committee approval to initiate the Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA II) in Italy. TIARA II is a 115-patient prospective clinical study evaluating the safety and performance of the Tiara™ Transcatheter Mitral Valve with the Tiara™ Transapical Delivery System (Tiara™). Following this approval, the first Italian TIARA II clinical study will begin before year end and the first enrollment early in the New Year. Approvals in additional geographies are expected in the first quarter of 2017. Data from this study is anticipated to be used to…

MondayNov 28, 2016 1:11 pm

NetworkNewsBreaks – Idera Pharmaceuticals (IDRA) Signs Exclusive License Agreement with Vivelix Pharmaceuticals for IMO-9200

Idera Pharmaceuticals (NASDAQ: IDRA) and Vivelix Pharmaceuticals Ltd. have entered into an exclusive license and collaboration agreement granting Vivelix worldwide rights to develop and market IMO-9200, an antagonist of TLR 7,8 and 9, for non-malignant gastrointestinal disorders. Per the agreement, Idera will receive an upfront fee of $15 million. In addition, Idera will be eligible for future IMO-9200-related development, regulatory and sales milestone payments totaling up to $140 million, as well as escalating royalties of global net sales. Idera is also responsible for developing potential back-up compounds to IMO-9200 if requested by and at Vivelix’s expense. As it relates to…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks